Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:21:59.135Z.
Consensus retrieved: 2026-10-06T12:02:22.797Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:21:59.135Z.
Quote observation: 2026-10-06T19:20:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9a1dfb6c252c1cf241c11dff63bdf10e98668db23039cc4017602387c5996572
Forward PE Ratio (N/A) = Dated Quote Price ($2.55) / Consensus Forward EPS ($-0.81)
FORWARD PE RATIO
N/A
Genelux Corporation
Market Cap
$114.34M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Genelux Corporation (GNLX) | $114.34M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.42M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $113.56M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.35M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.53M | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.27M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $111.72M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $118.07M | N/A |
| BGM Group Ltd. (BGM)vs › | $118.63M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.55, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.81 | $-0.81 – $-0.80 | 4 | n/m |
| 2027-12-31 | $-0.75 | $-0.85 – $-0.65 | 4 | n/m |
| 2028-12-31 | $-0.15 | $-0.63 – $0.39 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
